Bora Pharmaceuticals CoTPE:6472 +1.74%87 Current Ratio is 1.45 as of Dec. 2025, which is 10% below its 10-year median of 1.61. GuruFocus rates TPE:6472 with a GF Score™ of 87/100 and a GF Value™ of NT$716.94 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 995 Drug Manufacturers companies, Bora Pharmaceuticals Co ranks worse than 67.14% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Bora Pharmaceuticals Co's current ratio for the quarter that ended in Dec. 2025 was 1.45.
Bora Pharmaceuticals Co has a current ratio of 1.45. It generally indicates good short-term financial strength.
The historical rank and industry rank for Bora Pharmaceuticals Co's Current Ratio or its related term are showing as below:
TPE:6472'
s Current Ratio Range Over the Past 10 Years
Min: 1.15 Med: 1.61 Max: 5.27
Current: 1.45
During the past 13 years, Bora Pharmaceuticals Co's highest Current Ratio was 5.27. The lowest was 1.15. And the median was 1.61.
TPE:6472's Current Ratio is ranked worse than 67.14% of 995
companies
in the Drug Manufacturers industry
Industry Median: 2
vs TPE:6472: 1.45
Bora Pharmaceuticals Co (TPE:6472) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Bora Pharmaceuticals Co Current Ratio Related Terms
Bora Pharmaceuticals Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bora Pharmaceuticals Co Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Bora Pharmaceuticals Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bora Pharmaceuticals Co (TPE:6472) has a Current Ratio of 1.45 as of Dec. 2025. This is 10% below median its historical median of 1.61. Over the past decade, Bora Pharmaceuticals Co's Current Ratio has ranged from 1.15 to 5.27. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #668 out of 995 companies in the Drug Manufacturers industry, placing it in the top 67.1%.
Is Bora Pharmaceuticals Co's Current Ratio too high?
Bora Pharmaceuticals Co's current Current Ratio of 1.45 is 10% below median its 10-year median of 1.61. Over the past 10 years, this metric has ranged from a low of 1.15 to a high of 5.27. The Drug Manufacturers industry median Current Ratio is 2.00. Bora Pharmaceuticals Co's value of 1.45 is 27.5% below this industry median. Based on the distribution chart, Bora Pharmaceuticals Co ranks #668 out of 995 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bora Pharmaceuticals Co has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #668 out of 995 companies for Current Ratio. This places Bora Pharmaceuticals Co in the lower half of its industry. The industry median Current Ratio is 2.00. Bora Pharmaceuticals Co's value of 1.45 is 27.5% below this benchmark. Historically, Bora Pharmaceuticals Co's own Current Ratio has ranged from 1.15 to 5.27 over the past decade. While the company's 10-year median is 1.61 vs. the industry median of 2.00, Bora Pharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bora Pharmaceuticals Co's current Current Ratio of 1.45 is 27.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bora Pharmaceuticals Co's current Current Ratio is 1.45, which is 10% below median its own 10-year median of 1.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$716.94, compared to a current price of NT$439.50 — trading 38.7% below its estimated fair value. The current Current Ratio is 1.45, which is 10% below median its 10-year median of 1.61 and 27.5% below the Drug Manufacturers industry median of 2.00. Bora Pharmaceuticals Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current Current Ratio is 1.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$439.50 is trading 38.7% below its estimated GF Value™ of NT$716.94.
GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for TPE:6472:
Current Ratio: 1.45 (10% below median its 10-year median of 1.61)
GF Value™: NT$716.94 vs. price of NT$439.50 (38.7% below fair value)
Industry Position: 27.5% below the Drug Manufacturers median (#668 of 995)
No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
87GF Score
Get the complete analysis for TPE:6472
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6472 has been successfully added to your 
